NCT04170205 (EtioNPF) is a clinical trial in Small Fiber Neuropathy, sponsored by University Hospital, Brest.

Who is sponsoring NCT04170205?

NCT04170205 is sponsored by University Hospital, Brest.

What condition does NCT04170205 study?

NCT04170205 studies Small Fiber Neuropathy.

Is NCT04170205 still recruiting?

NCT04170205 is currently status unknown. Last updated 20 November 2019.

Last reviewed 2019-11-20 · How we verify

NCT04170205: EtioNPF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Causes Associated With Small Fiber Neuropathy (SFN).

Status unknown Last updated 20 November 2019

What this trial tests

trial in Small Fiber Neuropathy in 450 participants. Status unknown.

Timeline

15 November 2019

Primary endpoint
30 April 2020

30 April 2020

Quick facts

Lead sponsor	University Hospital, Brest
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	450
Start date	15 November 2019
Primary completion	30 April 2020
Estimated completion	30 April 2020
Sites	1 location across France

Conditions studied

Small Fiber Neuropathy — all drugs for Small Fiber Neuropathy →

Sponsor

University Hospital, Brest

Who can join

18 and older, any sex, with Small Fiber Neuropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Small fiber neuropathy (SFN) is an injury of cutaneous nerve fibers, mainly by a decrease in their density within the cutaneous tissue. The symptomatology associated with this SFN is broad with symptoms that are essentially sensory, but also autonomic. The etiologies of SFN are numerous (diabetes, drug, infectious, immunological...) and clinically non-specific, justifying a broad etiological assessment. The appearance of staged skin biopsies in the SFN balance sheet has greatly helped to improve diagnosis. Despite this, a significant part of SFN remains without associated etiology and is considered idiopathic. As the distribution of the different causes of SFN remains a missing data to date, the completion of this cohort study by one of the SFN reference centres should make it possible to establish the prevalence of SFN causes over a large population. Only patients with clinical symptoms that may be related to SFN and who have been sampled for SFN, positive or not, will be eligible for recruitment. The result of the anatomopathological sampling will allow patients to be separated into two groups, with or without SFN. The main judgement criteria will be the prevalence of etiologies associated with SFN: diabetes, medication, systemic lupus erythematosus, Gougerot-Sjögren syndrome, amylosis, dysthyroidism, alcoholism, vitamin B12 deficiency, HIV infection, hepatitis C, paraneoplastic syndrome, hereditary disease (Fabry disease, Friedreich ataxia,...), idiopathic, others.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Observational case-control study of small-fiber neuropathies, with regards on smoking and vitamin D deficiency and other possible causes.
Fouchard M, Brenaut E, Genestet S, Ficheux AS, et al · · 2022 · cited 5× · PMID 36714112 · DOI 10.3389/fmed.2022.1051967

Verify or expand the search:

Other recruiting trials for Small Fiber Neuropathy

Currently open trials in the same condition.

NCT04153422 — IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies · Phase 2 · recruiting
NCT04759443 — Detection of Small Fiber Neuropathy Using Skin Properties · recruiting
NCT04310644 — Autonomic Small Fiber Neuropathy and Ehlers Danlos Syndromes - Prospective Study and Registry · recruiting
NCT03509064 — Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy · recruiting

Other University Hospital, Brest trials

Trials by the same sponsor.

NCT07526688 — Aerobic Physical Activity and Orofacial Myofascial Pain · NA · not yet recruiting
NCT07487155 — Unified Junction of Care, Integrated Treatments and Team Coordination for ADHD in Prison Settings With Substance Use Dis · NA · not yet recruiting
NCT07417605 — Diagnostic Performance Of 4D Dynamic LAFOV FDG-PET Acquisition for Differentiation of Residual Disease and Post-radiatio · not yet recruiting
NCT07302074 — Understanding of Rare Inflammatory Arthritis in Comparison to Classical Inflammatory Arthritis : Tissular Observations a · NA · recruiting
NCT06441773 — Impact of Respiratory Rehabilitation on Quality of Life in Patients With Metastatic Non-small Cell Lung Cancer Treated W · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04170205 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Brest
Last refreshed: 20 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04170205.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing